RF
REGN icon

Roxbury Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Roxbury Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.87K Hold
9
– – 0.01% 353
2026
Q2 		$5.65K Hold
9
– – ﹤0.01% 339
2026
Q1 		$6.99K Hold
9
– – 0.01% 315
2025
Q4 		$6.98K Hold
9
– – 0.01% 311
2025
Q3 		$5.08K Hold
9
– – ﹤0.01% 314
2025
Q2 		$4.73K Buy
+9
New +$5.02K ﹤0.01% 311

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return
JC
Jacobs & Co San Francisco, California $1.16B AUM 34.03% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Roxbury Financial's REGN Position: Q3 2026 in Review

Roxbury Financial held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 9 shares worth $6.87K. The position accounts for 0.01% of the portfolio, ranked #353.

Roxbury Financial first reported a position in REGN in Q2 2025 and has held it in 6 quarters since. The position peaked at $6.99K in Q1 2026. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Roxbury Financial held 9 shares of Regeneron Pharmaceuticals worth $6.87K as of Q3 2026.
  • Roxbury Financial left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.01% of Roxbury Financial's portfolio in Q3 2026, its #353 holding.
  • Roxbury Financial first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Roxbury Financial's Regeneron Pharmaceuticals position peaked at $6.99K in Q1 2026.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Roxbury Financial's 13F filing for Q3 2026, filed 1 Oct 2026.